

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Ribo Life Science Co., Ltd.

蘇州瑞博生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING OF H SHARES OF THE COMPANY BY A DIRECTOR

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has recently been informed by Dr. GAN Liming (“**Dr. GAN**”), an executive Director, co-chief executive officer and global research and development president of the Company, that Dr. GAN has further purchased 6,800 H shares of the Company (the “**H Shares**”) (the “**Increase in Shareholding**”) on the open market with his own funds. Following the Increase in Shareholding, Dr. GAN has purchased an aggregate of 20,000 H Shares on the open market with his own funds as of July 10, 2026.

As advised by Dr. GAN, he is fully confident about the overall development prospects and potential growth of the Group. Subject to compliance with applicable laws and regulatory requirements, Dr. GAN does not rule out that he may further increase his shareholding in the Company as and when appropriate.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, July 10, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.